Blonanserin API: Market Size, Forecast & Strategic Trends 2026-2032
公開 2026/04/01 18:00
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Blonanserin API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Blonanserin API market, including market size, share, demand, industry development status, and forecasts for the next few years.
For pharmaceutical manufacturers, contract development organizations, and generic drug developers targeting the antipsychotic market, Blonanserin API—the active pharmaceutical ingredient for blonanserin drug products—represents a specialized opportunity within the atypical antipsychotic class. As a selective antagonist of dopamine D2 and serotonin 5-HT2A receptors, blonanserin offers a favorable efficacy and tolerability profile for schizophrenia management. With increasing generic penetration, expanding geographic availability, and growing demand for high-quality pharmaceutical-grade API meeting GMP and pharmacopoeial standards, the Blonanserin API market is positioned for sustained growth, driven by formulation manufacturers seeking reliable, high-purity supply sources.
The global market for Blonanserin API was estimated to be worth US$ 68 million in 2025 and is projected to reach US$ 126 million, growing at a CAGR of 9.3% from 2026 to 2032. In 2024, global Blonanserin API production reached approximately 26 tons, with an average global market price of around US$ 3,300 per kilogram. Blonanserin API is the active pharmaceutical ingredient used to manufacture blonanserin drug products. It is an atypical antipsychotic that exerts therapeutic effects primarily by antagonizing dopamine D2 and serotonin 5-HT2A receptors. Clinically indicated for the treatment of schizophrenia and related psychiatric disorders, the API is provided to formulation manufacturers in pharmaceutical-grade quality (meeting GMP and pharmacopoeial standards) and offered in various purity grades and packaging forms for tablet or other dosage form production.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/6095420/blonanserin-api
Product Segmentation and Purity Grades
The market is segmented by purity grade into ≥98% and ≥99% purity. The ≥99% purity segment accounts for approximately 68% of total market value in 2024, driven by regulatory requirements for high-purity API in finished pharmaceutical formulations and the premium pricing associated with higher purity specifications.
Purity grade selection is influenced by formulation requirements, regulatory standards, and cost considerations. The ≥98% grade is typically utilized in certain generic formulations and in markets with less stringent purity requirements, while the ≥99% grade is preferred for innovator products and markets with rigorous pharmacopoeial compliance standards.
Formulation Segmentation and Dosage Forms
By application, the market is segmented into tablets, powders, and others. Tablets represent the dominant dosage form, accounting for approximately 85% of Blonanserin API consumption in 2024, reflecting the established oral solid dosage form for chronic schizophrenia management.
The “others” segment includes potential alternative formulations such as orally disintegrating tablets, extended-release formulations, and parenteral dosage forms under development. According to QYResearch’s formulation tracking, several manufacturers are exploring modified-release formulations to improve dosing convenience and patient adherence.
Market Drivers and Clinical Landscape
Multiple factors are driving market growth. First, the global burden of schizophrenia: affecting approximately 24 million people worldwide, schizophrenia represents a persistent therapeutic need with ongoing demand for antipsychotic medications. Second, generic expansion: following patent expirations, generic versions of blonanserin have entered multiple markets, driving API volume growth. Third, geographic expansion: blonanserin’s market presence is expanding beyond its origin market in Japan into other Asian markets and potentially Western regions, supported by clinical data and regulatory approvals.
A representative case involves a Chinese API manufacturer that successfully completed regulatory filing with the U.S. FDA for Blonanserin API in Q1 2025. According to company disclosures shared with QYResearch, the approval enables entry into the regulated U.S. generic market, with anticipated API volume increases of 40–50% over the subsequent 18 months.
Regulatory Landscape and Quality Standards
Regulatory frameworks for Blonanserin API are governed by pharmacopoeial standards and GMP requirements. The Japanese Pharmacopoeia (JP) has established specifications for blonanserin, reflecting its origin and primary market. The United States Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.) standards apply in their respective markets for generic formulations.
Key regulatory requirements include:
Impurity profiling: Control of related substances, including process impurities and degradation products.
Residual solvents: Compliance with ICH Q3C guidelines.
Stability testing: Demonstration of stability under ICH conditions to establish shelf life.
GMP compliance: Manufacturing facilities must comply with current Good Manufacturing Practices.
Recent regulatory trends include increasing harmonization across markets, with suppliers seeking multiple pharmacopoeial certifications to serve diverse geographic markets. According to QYResearch’s regulatory analysis, the number of Blonanserin API manufacturers with multiple pharmacopoeial certifications increased by 35% from 2023 to 2025.
Exclusive Observation: Geographic Concentration and Emerging Competition
A defining characteristic of the Blonanserin API market is its geographic concentration in Asia, with Japanese and Chinese manufacturers dominating global supply. Sumitomo Pharma—the innovator—has historically led the market, with Japanese manufacturing capabilities.
However, the landscape is evolving as Chinese manufacturers—including HeBei Guolong Pharmaceutical, Zhejiang Guobang Pharmaceutical, and Zhejiang Jinhua Conba BIO-PHARM—expand production capacity and pursue regulatory approvals in regulated markets. According to QYResearch’s capacity analysis, Chinese manufacturers collectively accounted for approximately 45% of global Blonanserin API production in 2025, up from 32% in 2023, reflecting aggressive capacity expansion and quality improvement initiatives.
This geographic shift is expected to continue, driven by:
Cost advantages in manufacturing and raw materials.
Improved regulatory compliance capabilities.
Domestic market growth in China following blonanserin’s inclusion in the National Reimbursement Drug List.
Market Segmentation
The Blonanserin API market is segmented as below:
Segment by Type:
Purity ≥98%
Purity ≥99%
Segment by Application:
Tablets
Powders
Others
Key Industry Participants
The market features a mix of innovator manufacturers and emerging generic API suppliers concentrated in Asia:
Sumitomo Pharma, HeBei Guolong Pharmaceutical, Kaneka Corporation, Tianish Laboratories, Cerata Pharmaceuticals, Lizhu Synthetic Pharmaceutical, Zhejiang Guobang Pharmaceutical, Zhejiang Jinhua Conba BIO-PHARM, Hunan Xiangzhong Pharmaceutical.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
For pharmaceutical manufacturers, contract development organizations, and generic drug developers targeting the antipsychotic market, Blonanserin API—the active pharmaceutical ingredient for blonanserin drug products—represents a specialized opportunity within the atypical antipsychotic class. As a selective antagonist of dopamine D2 and serotonin 5-HT2A receptors, blonanserin offers a favorable efficacy and tolerability profile for schizophrenia management. With increasing generic penetration, expanding geographic availability, and growing demand for high-quality pharmaceutical-grade API meeting GMP and pharmacopoeial standards, the Blonanserin API market is positioned for sustained growth, driven by formulation manufacturers seeking reliable, high-purity supply sources.
The global market for Blonanserin API was estimated to be worth US$ 68 million in 2025 and is projected to reach US$ 126 million, growing at a CAGR of 9.3% from 2026 to 2032. In 2024, global Blonanserin API production reached approximately 26 tons, with an average global market price of around US$ 3,300 per kilogram. Blonanserin API is the active pharmaceutical ingredient used to manufacture blonanserin drug products. It is an atypical antipsychotic that exerts therapeutic effects primarily by antagonizing dopamine D2 and serotonin 5-HT2A receptors. Clinically indicated for the treatment of schizophrenia and related psychiatric disorders, the API is provided to formulation manufacturers in pharmaceutical-grade quality (meeting GMP and pharmacopoeial standards) and offered in various purity grades and packaging forms for tablet or other dosage form production.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/6095420/blonanserin-api
Product Segmentation and Purity Grades
The market is segmented by purity grade into ≥98% and ≥99% purity. The ≥99% purity segment accounts for approximately 68% of total market value in 2024, driven by regulatory requirements for high-purity API in finished pharmaceutical formulations and the premium pricing associated with higher purity specifications.
Purity grade selection is influenced by formulation requirements, regulatory standards, and cost considerations. The ≥98% grade is typically utilized in certain generic formulations and in markets with less stringent purity requirements, while the ≥99% grade is preferred for innovator products and markets with rigorous pharmacopoeial compliance standards.
Formulation Segmentation and Dosage Forms
By application, the market is segmented into tablets, powders, and others. Tablets represent the dominant dosage form, accounting for approximately 85% of Blonanserin API consumption in 2024, reflecting the established oral solid dosage form for chronic schizophrenia management.
The “others” segment includes potential alternative formulations such as orally disintegrating tablets, extended-release formulations, and parenteral dosage forms under development. According to QYResearch’s formulation tracking, several manufacturers are exploring modified-release formulations to improve dosing convenience and patient adherence.
Market Drivers and Clinical Landscape
Multiple factors are driving market growth. First, the global burden of schizophrenia: affecting approximately 24 million people worldwide, schizophrenia represents a persistent therapeutic need with ongoing demand for antipsychotic medications. Second, generic expansion: following patent expirations, generic versions of blonanserin have entered multiple markets, driving API volume growth. Third, geographic expansion: blonanserin’s market presence is expanding beyond its origin market in Japan into other Asian markets and potentially Western regions, supported by clinical data and regulatory approvals.
A representative case involves a Chinese API manufacturer that successfully completed regulatory filing with the U.S. FDA for Blonanserin API in Q1 2025. According to company disclosures shared with QYResearch, the approval enables entry into the regulated U.S. generic market, with anticipated API volume increases of 40–50% over the subsequent 18 months.
Regulatory Landscape and Quality Standards
Regulatory frameworks for Blonanserin API are governed by pharmacopoeial standards and GMP requirements. The Japanese Pharmacopoeia (JP) has established specifications for blonanserin, reflecting its origin and primary market. The United States Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.) standards apply in their respective markets for generic formulations.
Key regulatory requirements include:
Impurity profiling: Control of related substances, including process impurities and degradation products.
Residual solvents: Compliance with ICH Q3C guidelines.
Stability testing: Demonstration of stability under ICH conditions to establish shelf life.
GMP compliance: Manufacturing facilities must comply with current Good Manufacturing Practices.
Recent regulatory trends include increasing harmonization across markets, with suppliers seeking multiple pharmacopoeial certifications to serve diverse geographic markets. According to QYResearch’s regulatory analysis, the number of Blonanserin API manufacturers with multiple pharmacopoeial certifications increased by 35% from 2023 to 2025.
Exclusive Observation: Geographic Concentration and Emerging Competition
A defining characteristic of the Blonanserin API market is its geographic concentration in Asia, with Japanese and Chinese manufacturers dominating global supply. Sumitomo Pharma—the innovator—has historically led the market, with Japanese manufacturing capabilities.
However, the landscape is evolving as Chinese manufacturers—including HeBei Guolong Pharmaceutical, Zhejiang Guobang Pharmaceutical, and Zhejiang Jinhua Conba BIO-PHARM—expand production capacity and pursue regulatory approvals in regulated markets. According to QYResearch’s capacity analysis, Chinese manufacturers collectively accounted for approximately 45% of global Blonanserin API production in 2025, up from 32% in 2023, reflecting aggressive capacity expansion and quality improvement initiatives.
This geographic shift is expected to continue, driven by:
Cost advantages in manufacturing and raw materials.
Improved regulatory compliance capabilities.
Domestic market growth in China following blonanserin’s inclusion in the National Reimbursement Drug List.
Market Segmentation
The Blonanserin API market is segmented as below:
Segment by Type:
Purity ≥98%
Purity ≥99%
Segment by Application:
Tablets
Powders
Others
Key Industry Participants
The market features a mix of innovator manufacturers and emerging generic API suppliers concentrated in Asia:
Sumitomo Pharma, HeBei Guolong Pharmaceutical, Kaneka Corporation, Tianish Laboratories, Cerata Pharmaceuticals, Lizhu Synthetic Pharmaceutical, Zhejiang Guobang Pharmaceutical, Zhejiang Jinhua Conba BIO-PHARM, Hunan Xiangzhong Pharmaceutical.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ